FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

DesJardin Michael A.

2. Date of Event Requiring Statement (MM/DD/YYYY)
2/22/2017 

3. Issuer Name and Ticker or Trading Symbol

Horizon Pharma plc [HZNP]

(Last)        (First)        (Middle)

C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE, 1ST FLOOR, 1 BURLINGTON RD

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
EVP, Technical Operations /

(Street)

DUBLIN, L2 4       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)     (1) 12/14/2026   Ordinary Shares   36813   $14.93   D    
Stock Option (Right to Buy)     (2) 2/20/2027   Ordinary Shares   17824   $17.19   D    
Restricted Stock Units (RSU)     (3)   (3) Ordinary Shares   23443     (3) D    
Restricted Stock Units (RSU)     (4)   (4) Ordinary Shares   8726     (4) D    

Explanation of Responses:
( 1)  25% of the shares subject to the option vest and become exercisable on the first anniversary of the date of grant (December 15, 2016), and the remaining shares vest in 36 equal monthly installments thereafter.
( 2)  25% of the shares subject to the option vest and become exercisable on the first anniversary of the date of grant (February 21, 2017), and the remaining shares vest in 36 equal monthly installments thereafter.
( 3)  Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% annually on each anniversary of the date of grant (December 15, 2016).
( 4)  Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% annually on each anniversary of the date of grant (February 21, 2017).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DesJardin Michael A.
C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE
1ST FLOOR, 1 BURLINGTON RD
DUBLIN, L2 4


EVP, Technical Operations

Signatures
/s/ Miles W. McHugh, Attorney-in-Fact 3/3/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Horizon Therapeutics Pub... Charts.
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Horizon Therapeutics Pub... Charts.